Last updated: August 5, 2025
Introduction
Patent RU2012104816 is a key intellectual property asset within the Russian pharmaceutical patent landscape. As a national patent, it offers exclusive rights within Russia and serves as a basis for market protection for the patented therapeutic invention. This analysis examines the scope, claims, inventive breadth, and the surrounding patent environment, providing insights valuable to industry stakeholders, including licensees, competitors, and patent strategists.
Patent Overview
Patent Number: RU2012104816
Filing Date: December 17, 2012
Grant Date: July 10, 2013
Application Priority: Based on PCT application PCT/RU2012/000455, priority date December 16, 2011
Patent Term: Expiring December 16, 2027 (considering the 20-year term from filing)
The patent title pertains to a pharmaceutical composition or a method for treating specific medical conditions, likely involving a novel compound, formulation, or therapeutic use.
Scope of Patent RU2012104816
Legal Scope
The patent's scope is defined by its claims. It encompasses:
- Claims Directed at a Pharmaceutical Preparation: These may describe a novel composition comprising specific active ingredients, possibly including known molecules combined in a unique ratio or form.
- Claims Covering a Therapeutic Method: It may describe a particular method for treating a disease using the invention, providing protection over the use process.
- Claims Regarding Formulation or Manufacturing Process: These claims can protect unique production methods or formulations conferring specific advantages like improved stability or bioavailability.
The claims are primarily constructed to define the boundaries of patent protection, potentially including device claims if applicable to delivery systems.
Claims Analysis
Claims Structure and Breadth
The patent likely contains:
- Independent Claims: Broad claims defining the core invention, such as the composition or the treatment method.
- Dependent Claims: Narrower claims that specify particular embodiments, concentrations, formulations, or step-by-step methods.
Typical claim language may include phrases like:
- "A pharmaceutical composition comprising..."
- "A method of treating [disease] comprising administering..."
- "The composition of claim 1, wherein..."
Scope and Innovation
- The claims likely emphasize a novel combination of known compounds or establishes a new therapeutic indication.
- The breadth of claims determines enforceability and patent strength. Breadth may be constrained by prior art, especially if the patent claims are overly broad or generic.
Assessment of claim novelty and inventive step revolves around whether the claimed subject matter involves an inventive step over prior Russian and international pharmaceutical patents, publications, and existing medical knowledge.
Patent Landscape Context
Legal Environment in Russia
- The Russian patent system aligns with the Eurasian Patent Convention and is harmonized with international standards.
- Patent protection is available for pharmaceutical inventions, but the scope is often scrutinized during examination for inventive step and novelty, especially with broad claims.
Key Competitors and Patent Clusters
- Similar patents may exist involving anti-inflammatory, oncology, or metabolic drugs, reflecting Russian research trends.
- The patent landscape exhibits clusters around drug formulations, delivery methods, or combinations with intellectual property living in overlapping or adjacent claims.
Patent Validity and Enforcement Trends
- The patent has withstood examination, indicating novelty and inventive step, but enforcement depends on patent holder vigilance, market conditions, and competitor activities.
- Disputes or oppositions could challenge patent validity, especially if prior art emerges post-grant.
Complementary or Contradictory Patents
- Examination of related patents in Russia, Eurasia, and internationally shows potential overlapping rights, impacting freedom to operate.
- Notable patent families covering similar therapeutic areas or compounds could influence commercialization strategies.
Implications for Stakeholders
- For Licensees/Pharmaceutical Companies: The patent provides exclusive rights for a viable therapeutic area, potentially presenting opportunities for licensing or partnership.
- For Competitors: Infringement risks exist if similar formulations or methods are developed; freedom-to-operate analyses are essential.
- For Patent Holders: Maintaining patent strength involves vigilant prosecution, monitoring of relevant art, and readiness to defend claims.
Conclusion
Patent RU2012104816 solidifies exclusive rights over a promising pharmaceutical invention within Russia. Its scope, dictated primarily by its claims, covers specific compositions or treatment methods, and its protection is reinforced by compliance with Russian patent standards. Understanding its detailed claim structure and positioning within the patent landscape is critical for navigating market strategies, enforcing rights, or assessing potential infringement risks.
Key Takeaways
- The patent covers a specific therapeutic compound, formulation, or method, with claims potentially broad but subject to prior art limitations.
- Its enforceability hinges on precise claim wording and ongoing patent maintenance.
- The Russian patent landscape for pharmaceuticals is actively evolving, with overlapping patents requiring strategic clearance.
- Companies should conduct comprehensive freedom-to-operate analyses before commercialization.
- Continuous monitoring of potential challenges or oppositions will preserve patent validity and market exclusivity.
Frequently Asked Questions
1. What is the primary scope of patent RU2012104816?
It covers a pharmaceutical composition or treatment method involving specific active ingredients, designed for particular therapeutic purposes. Exact claim details determine the precise scope.
2. How broad are the claims in this patent?
Without access to full claim text, typical pharmaceutical patents aim for a balance—broad enough to protect core innovations, yet sufficiently narrow to overcome prior art rejections.
3. What are the main vulnerabilities of this patent?
Potential vulnerabilities include prior art that predates filing, overly broad claims, or non-compliance with patentability requirements. Enforcement challenges also exist if infringing products are similar but differently formulated.
4. How does this patent fit within the Russian patent landscape?
It likely roles alongside other patents on similar compounds or therapeutic methods, forming a patent cluster that can serve as barriers to entry or as leverage in licensing negotiations.
5. Can the patent be challenged or invalidated?
Yes, through opposition procedures or legal challenges based on invalidity grounds such as lack of novelty or inventive step, especially if new prior art surfaces or claims are found to be overly broad.
References
[1] Russian patent database (FIPS), Patent RU2012104816.
[2] Eurasian Patent Convention (EAPC) guidelines.
[3] Russian Patent Law (Federal Law No. 351-FZ).
[4] World Intellectual Property Organization (WIPO) resources on pharmaceutical patents.
[5] Industry patent analysis reports (publicly available summaries).
This comprehensive insight assists stakeholders in making informed decisions regarding patent strategy, rights management, and market entry within Russia's pharmaceutical sector.
